Search - tctmd.com

Displaying 241 - 260 of 415

Sort: Relevancy | Date

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

Yael L. Maxwell

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Daily News

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Caitlin E. Cox

August 24, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Industry News

FDA approves new antiplatelet drug used during heart procedure

June 24, 2015

News Daily News

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

June 09, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Meta-analyses Shed Light on the Impact of DAPT Duration

Caitlin E. Cox

April 03, 2015

Advertisement

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

FDA approves new antiplatelet drug used during heart procedure

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

Meta-analyses Shed Light on the Impact of DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content